CN101851238B - 取代的8-杂芳基黄嘌呤 - Google Patents

取代的8-杂芳基黄嘌呤 Download PDF

Info

Publication number
CN101851238B
CN101851238B CN2010101556967A CN201010155696A CN101851238B CN 101851238 B CN101851238 B CN 101851238B CN 2010101556967 A CN2010101556967 A CN 2010101556967A CN 201010155696 A CN201010155696 A CN 201010155696A CN 101851238 B CN101851238 B CN 101851238B
Authority
CN
China
Prior art keywords
alkyl
compound
pyridyl
xanthine
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2010101556967A
Other languages
English (en)
Chinese (zh)
Other versions
CN101851238A (zh
Inventor
G·王
J·M·里格尔
R·D·汤普森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Erjian Sales Co ltd
Original Assignee
Adenosine Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adenosine Therapeutics LLC filed Critical Adenosine Therapeutics LLC
Publication of CN101851238A publication Critical patent/CN101851238A/zh
Application granted granted Critical
Publication of CN101851238B publication Critical patent/CN101851238B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2010101556967A 2003-08-25 2004-08-20 取代的8-杂芳基黄嘌呤 Expired - Fee Related CN101851238B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49787503P 2003-08-25 2003-08-25
US60/497875 2003-08-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2004800314554A Division CN1894250B (zh) 2003-08-25 2004-08-20 取代的8-杂芳基黄嘌呤

Publications (2)

Publication Number Publication Date
CN101851238A CN101851238A (zh) 2010-10-06
CN101851238B true CN101851238B (zh) 2012-07-18

Family

ID=34272616

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2004800314554A Expired - Fee Related CN1894250B (zh) 2003-08-25 2004-08-20 取代的8-杂芳基黄嘌呤
CN2010101556967A Expired - Fee Related CN101851238B (zh) 2003-08-25 2004-08-20 取代的8-杂芳基黄嘌呤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2004800314554A Expired - Fee Related CN1894250B (zh) 2003-08-25 2004-08-20 取代的8-杂芳基黄嘌呤

Country Status (19)

Country Link
US (3) US7342006B2 (enExample)
EP (2) EP1658291B1 (enExample)
JP (1) JP4769721B2 (enExample)
KR (1) KR101222364B1 (enExample)
CN (2) CN1894250B (enExample)
AR (1) AR045499A1 (enExample)
AU (1) AU2004268964B2 (enExample)
BR (1) BRPI0413922B8 (enExample)
CA (1) CA2536553C (enExample)
DK (2) DK2295434T3 (enExample)
ES (2) ES2440467T3 (enExample)
IL (1) IL173723A (enExample)
NZ (1) NZ545715A (enExample)
PL (1) PL1658291T3 (enExample)
PT (1) PT1658291E (enExample)
RU (1) RU2357969C2 (enExample)
TW (1) TWI362390B (enExample)
WO (1) WO2005021548A2 (enExample)
ZA (1) ZA200602333B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ532062A (en) * 2001-10-01 2006-09-29 Univ Virginia 2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
WO2003063800A2 (en) * 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists
JP4769721B2 (ja) * 2003-08-25 2011-09-07 トロヴィス ファーマシューティカルズ リミテッド ライアビリティ カンパニー 置換8−ヘテロアリールキサンチン
JP5046930B2 (ja) * 2004-08-02 2012-10-10 ユニバーシティ オブ バージニア パテント ファウンデーション A2aアゴニスト活性を有する修飾5’−リボース基を備えた2−プロピニルアデノシン類似体
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580855A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
CN101090724A (zh) 2004-09-20 2007-12-19 泽农医药公司 用于抑制人硬脂酰CoA去饱和酶的吡啶衍生物
MX2007003319A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
MX2007003318A (es) 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
WO2006091936A2 (en) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
RU2415858C2 (ru) * 2005-06-16 2011-04-10 Си Ви Терапьютикс, Инк. Пролекарства антагонистов a2b рецептора аденозина
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
CA2618653A1 (en) 2005-08-12 2007-02-22 Takeda Pharmaceutical Company Limited Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
US20070059740A1 (en) * 2005-08-26 2007-03-15 Linden Joel M Method of targeting a2b adenosine receptor antagonist therapy
US7566401B2 (en) 2005-10-03 2009-07-28 Kelm Mark A Process for separating and isolating xanthines, individual polar protic monomers, and polar protic oligomers
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
GB0606774D0 (en) * 2006-04-03 2006-05-10 Novartis Ag Organic compounds
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
UA105164C2 (en) 2006-06-16 2014-04-25 Догвуд Фармасьютикалз, Инк Substituted 8-[6-amino-3-pyridyl]xanthines
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US8193200B2 (en) * 2007-01-04 2012-06-05 University Of Virginia Patent Foundation Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
RU2344137C1 (ru) * 2007-07-18 2009-01-20 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) Производные 8-амино-7-(2-гидроксипропил-1)-1,3-диметилксантина гидрохлорида, проявляющие гемореологическую активность
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
BRPI0909157A2 (pt) 2008-03-26 2015-11-24 Advinus Therapeutics Private Ltd compostos heterocíclicos como antagonistas de receptores de adenosina
US20110118276A1 (en) * 2008-07-16 2011-05-19 Edward Leung Methods of treating atherosclerosis
US8859566B2 (en) 2009-03-13 2014-10-14 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
RU2404181C1 (ru) * 2009-06-02 2010-11-20 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) 3-метил-8-пиперазино-7-(тиетанил-3)-1-этилксантина гидрохлорид, проявляющий антиагрегационную и дезагрегационную активность
WO2011005871A1 (en) 2009-07-07 2011-01-13 Pgxhealth, Llc Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists
US8796290B2 (en) 2009-11-09 2014-08-05 Advinus Therapeutics Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
AU2011303420B2 (en) 2010-09-13 2014-03-20 Impetis Biosciences Ltd. Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications
EP2465859A1 (en) * 2010-12-08 2012-06-20 Life & Brain GmbH 8-Triazolylxanthine derivatives, processes for their production and their use as adenosine receptor antagonists
CN102532137B (zh) * 2011-12-05 2014-12-10 辽宁医学院 8-吡唑取代黄嘌呤类a2b腺苷受体拮抗剂及其合成方法和应用
EP3389664A4 (en) 2015-12-14 2020-01-08 Raze Therapeutics Inc. MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
US11548867B2 (en) 2017-07-19 2023-01-10 Idea Ya Biosciences, Inc. Amido compounds as AhR modulators
EP4126866A1 (en) * 2020-03-26 2023-02-08 Inspyr Therapeutics, Inc. 8-substituted diaryl xanthines as dual a2a-a2b antagonists
BR112023023996A2 (pt) * 2021-05-18 2024-01-30 Adovate Llc Xantinas de piridil contendo amida cíclica como antagonistas de a2b
CN113262882B (zh) * 2021-07-21 2021-09-17 北京矿冶研究总院 阳离子捕收剂、制备方法及在磷矿反浮选中的应用
WO2024050825A1 (en) * 2022-09-09 2024-03-14 National Institute Of Biological Sciences, Beijing Compounds as mlkl inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2443023A1 (en) * 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
AU1507099A (en) * 1997-12-15 1999-07-05 Kyowa Hakko Kogyo Co. Ltd. Preventives/remedies for sleep disturbance
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
ATE319452T1 (de) * 1999-10-29 2006-03-15 Kyowa Hakko Kogyo Kk Arzneimittel gegen essstörungen
JP2003535818A (ja) * 2000-02-17 2003-12-02 スィーヴィー セラピューティクス インコーポレイテッド 哺乳動物細胞増殖を媒介するa2bアデノシンリセプタ拮抗剤の同定および使用方法
PT1444233E (pt) 2001-11-09 2011-09-29 Gilead Palo Alto Inc Antagonistas de receptor de adenosina a2b
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7034070B2 (en) * 2002-09-27 2006-04-25 Vincent Chuang Arylalkyl aminofunctional silanes for epoxy laminates
US7148229B2 (en) 2003-02-19 2006-12-12 Hoffman-La Roche Inc. Sulfonamide substituted xanthine derivatives
JP4769721B2 (ja) * 2003-08-25 2011-09-07 トロヴィス ファーマシューティカルズ リミテッド ライアビリティ カンパニー 置換8−ヘテロアリールキサンチン
JP4929173B2 (ja) 2004-09-01 2012-05-09 ギリアード・パロ・アルト・インコーポレイテッド A2bアデノシンレセプターアンタゴニストを使用する創傷治癒の方法
RU2391103C2 (ru) 2004-10-15 2010-06-10 Си Ви Терапьютикс, Инк. Способ предупреждения и лечения ремоделирования дыхательных путей и воспаления легких с применением антагонистов аденозиновых рецепторов a2b
US7579348B2 (en) 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
WO2006091936A2 (en) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091896A2 (en) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyridyl substituted xanthines
WO2006091898A2 (en) 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
RU2415858C2 (ru) 2005-06-16 2011-04-10 Си Ви Терапьютикс, Инк. Пролекарства антагонистов a2b рецептора аденозина
NZ571324A (en) * 2006-03-17 2011-07-29 Gilead Palo Alto Inc Method of preventing and treating hepatic disease using A2B adenoise receptor antagonists
US7884100B2 (en) 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
BRPI0909157A2 (pt) * 2008-03-26 2015-11-24 Advinus Therapeutics Private Ltd compostos heterocíclicos como antagonistas de receptores de adenosina

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2443023A1 (en) * 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUZ"MENKO.I.I et al.REACTIONS OF THEOPHYLLINES. CHEMICAL CONVERSIONS OF 8-AMINOTHEOPHYLLINATES.《Chemistry of Heterocyclic Compounds》.2000,第36卷(第8期),963-970. *

Also Published As

Publication number Publication date
TWI362390B (en) 2012-04-21
KR20060132549A (ko) 2006-12-21
BRPI0413922B8 (pt) 2021-05-25
WO2005021548A3 (en) 2005-06-30
KR101222364B1 (ko) 2013-01-15
AR045499A1 (es) 2005-11-02
RU2006109474A (ru) 2007-10-10
EP2295434A2 (en) 2011-03-16
JP2007503443A (ja) 2007-02-22
US20080200456A1 (en) 2008-08-21
US7732455B2 (en) 2010-06-08
EP2295434A3 (en) 2011-07-27
BRPI0413922B1 (pt) 2018-08-28
AU2004268964B2 (en) 2010-03-11
CN1894250A (zh) 2007-01-10
DK2295434T3 (en) 2015-12-14
AU2004268964A1 (en) 2005-03-10
CN101851238A (zh) 2010-10-06
CA2536553C (en) 2013-01-29
TW200524931A (en) 2005-08-01
RU2357969C2 (ru) 2009-06-10
BRPI0413922A (pt) 2006-10-24
EP2295434B1 (en) 2015-09-30
EP1658291B1 (en) 2013-10-02
HK1096397A1 (en) 2007-06-01
US7342006B2 (en) 2008-03-11
CN1894250B (zh) 2010-06-09
DK1658291T3 (da) 2013-10-28
CA2536553A1 (en) 2005-03-10
ES2440467T3 (es) 2014-01-29
US20100273780A1 (en) 2010-10-28
WO2005021548A2 (en) 2005-03-10
US20050065341A1 (en) 2005-03-24
ES2557310T3 (es) 2016-01-25
NZ545715A (en) 2009-02-28
JP4769721B2 (ja) 2011-09-07
EP1658291A2 (en) 2006-05-24
HK1148518A1 (en) 2011-09-09
PT1658291E (pt) 2013-10-21
IL173723A (en) 2015-01-29
PL1658291T3 (pl) 2014-03-31
IL173723A0 (en) 2006-07-05
ZA200602333B (en) 2007-04-25

Similar Documents

Publication Publication Date Title
CN101851238B (zh) 取代的8-杂芳基黄嘌呤
US7579348B2 (en) Derivatives of 8-substituted xanthines
US8153628B2 (en) Pyrazolyl substituted xanthines
US7601723B2 (en) Pyridyl substituted xanthines
US8258142B2 (en) Substituted 8-[6-amino-3-pyridyl]xanthines
US7875608B2 (en) Substituted 8-[6-amino-3pyridyl]xanthines
CN101466382A (zh) 取代的8-[6-氨基-3-吡啶基]黄嘌呤
HK1148518B (en) Substituted 8-heteroaryl xanthines
HK1096397B (en) Substituted 8-heteroaryl xanthines
MXPA06002223A (en) Substituted 8-heteroaryl xanthines
HK1131569A (en) Substituted 8-[6-amino-3-pyridyl]xanthines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1148518

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1148518

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: TROVIS PHARMACEUTICALS LLC

Free format text: FORMER OWNER: ZHUOWEISI PHARMACEUTICAL CO., LTD.

Effective date: 20131024

Owner name: DOUG WOOD MEDICINE CORP.

Free format text: FORMER OWNER: CLINICAL DATA INC.

Effective date: 20131024

Owner name: FURUISITE LABORATORY HOLDING CO., LTD.

Free format text: FORMER OWNER: DOUG WOOD MEDICINE CORP.

Effective date: 20131024

Owner name: DOUG WOOD MEDICINE CORP.

Free format text: FORMER OWNER: FURUISITE LABORATORY HOLDING CO., LTD.

Effective date: 20131024

Owner name: CLINICAL DATA INC.

Free format text: FORMER OWNER: TROVIS PHARMACEUTICALS LLC

Effective date: 20131024

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20131024

Address after: Virginia

Patentee after: Dogwood Pharmaceuticals, Inc.

Address before: Bermuda Hamill

Patentee before: Laboratory of Forest Holdings Ltd.

Effective date of registration: 20131024

Address after: Bermuda Hamill

Patentee after: Laboratory of Forest Holdings Ltd.

Address before: Virginia

Patentee before: Dogwood Pharmaceuticals, Inc.

Effective date of registration: 20131024

Address after: Virginia

Patentee after: Dogwood Pharmaceuticals, Inc.

Address before: American New York

Patentee before: Clinical Data Inc.

Effective date of registration: 20131024

Address after: American New York

Patentee after: Clinical Data Inc.

Address before: American New York

Patentee before: Travis Pharmaceutical Holdings

Effective date of registration: 20131024

Address after: American New York

Patentee after: Travis Pharmaceutical Holdings

Address before: Massachusetts, USA

Patentee before: Zhuowei Pharmaceutical Co.,Ltd.

TR01 Transfer of patent right

Effective date of registration: 20210729

Address after: New jersey, USA

Patentee after: Erjian Sales Co.,Ltd.

Address before: Virginia

Patentee before: Dogwood Pharmaceuticals, Inc.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120718

CF01 Termination of patent right due to non-payment of annual fee